局部晚期非小细胞肺癌放化疗后心包积液的发病率与预测因素
本研究基于2期前瞻性随机试验中201例接受质子束或调强放疗(60-74 Gy)同步化疗的局部晚期非小细胞肺癌患者,发现心包积液(PCE)1年累积发病率31.4%、2年45.4%,中位发生时间8.9个月。
要点
- 放化疗后PCE常见,2年累积发病率近半数(45.4%)。
- 心脏HV35>10%是PCE最强独立预测因素(HR 2.14)。
- 辅助化疗和既往心脏病亦增加PCE风险。
核心结论
- PCE是局部晚期非小细胞肺癌放化疗后常见心脏毒性,即使心脏受照剂量中等仍近半数发生。
- HV35>10%可识别PCE高风险患者,辅助化疗可能增加风险。
研究设计与样本
- 前瞻性2期随机试验纳入2009年7月至2014年4月201例局部晚期非小细胞肺癌患者,接受质子束或调强放疗60-74 Gy同步化疗。
- 主要终点为≥2级PCE,通过随访影像诊断,采用Cox比例风险模型和递归分割分析识别相关因素。
- 另在301例回顾性队列中评估可重复性。
主要发现
- 试验队列PCE 1年累积发病率31.4%,2年45.4%,中位发生时间8.9个月。
关键数值与推荐
- 心脏HV35(接受≥35 Gy体积)>10%为PCE独立预测阈值。
- 心脏剂量体积参数V20至V65均预测PCE,HV35关联最强。
临床怎么用
- 放疗计划时应关注心脏HV35,尽量控制在10%以下以降低PCE风险。
- 对接受辅助化疗或既往有心脏病的患者,应加强心包积液监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Findings from Radiation Therapy Oncology Group (RTOG) 0617 suggested that collateral radiation to the heart may contribute to early death in patients receiving chemoradiation therapy for non-small cell lung cancer (NSCLC); however, reports of cardiac toxicity after thoracic radiation therapy (RT) remain limited. Because pericardial disease is the most common cardiac complication of thoracic RT, we investigated the incidence of and risk factors for pericardial effusion (PCE) in patients enrolled in a phase 2 prospective randomized study of intensity modulated RT versus proton therapy for locally advanced NSCLC. METHODS AND MATERIALS: From July 2009 through April 2014, 201 patients were prospectively treated with proton beam therapy or intensity modulated RT to 60 to 74 Gy with concurrent chemotherapy. The primary endpoint (grade ≥2 PCE) was diagnosed on review of follow-up images. Clinical characteristics and cardiac dose-volume parameters associated with PCE were identified via Cox proportional hazards modeling and recursive partitioning analysis of null Martingale residuals. Reproducibility was evaluated in a separate retrospective cohort of 301 patients. RESULTS: The cumulative incidence rates of PCE among patients in the trial were 31.4% at 1 year and 45.4% at 2 years, with a median time to PCE of 8.9 months. Several cardiac dose-volume parameters (eg, V20 [volume receiving ≥20 Gy] to V65 [volume receiving ≥65 Gy]) predicted PCE, but heart volume receiving ≥35 Gy (HV35) was the most strongly associated, with a cutoff volume of 10%. On multivariate analysis, HV35 >10% independently predicted PCE (hazard ratio [HR], 2.14; P=.002), a finding that maintained reproducibility in the retrospective validation cohort. Other factors associated with PCE included receipt of adjuvant chemotherapy (HR, 2.82; P<.001) and prior cardiac disease (HR, 1.68; P=.020). CONCLUSIONS: PCE was common after RT for NSCLC, occurring in nearly half of patients even after moderate radiation doses to the heart. Adjuvant chemotherapy may increase the risk of PCE, and HV35 >10% may identify patients at risk of development of this cardiac toxicity.
引用
- Ning MS, Tang L, Gomez DR, et al. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816165. doi:10.1016/j.ijrobp.2017.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。